Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Persistent head dyskinesias following STN DBS in Parkinson’s disease resolve using directionality
Objective: To control subthalamic nucleus deep brain stimulation (STN DBS) induced dyskinesias in Parkinson's disease (PD) using directionality. Background: Levodopa-induced dyskinesias (LID) frequently occur in…Intrinsic brain functional connectivity predicts treatment-related motor complications in drug-naive Parkinson’s disease patients
Objective: Using resting-state functional MRI, we investigated intrinsic brain networks connectivity at baseline in a cohort of drug-naïve Parkinson’s disease (PD) patients which successively developed treatment-related…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Home videos made on smart phone supplements paper based diary for correct identification of Motor states in Parkinson’s disease
Objective: We aimed to assess the feasibility of home videos made on smart phone as a supplemental tool to paper based diary in registering the…Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…Combined therapy VS only levodopa therapy in a 5-years follow up cohort
Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…Real-World Evidence for a Smartwatch-based Parkinson’s Motor Assessment App in Patients Undergoing Therapy Changes
Objective: We sought to investigate patient and clinician usability of a smartwatch-based wearable motor assessment system for measuring Parkinson’s disease (PD) motor symptoms in patients undergoing…Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease
Objective: To investigate with PET and the radioligand [11C]PHNO whether levodopa-induced dyskinesias in Parkinson disease (PD) are associated with dopamine-D3 receptor (D3R) overexpression in substantia nigra…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 40
- Next Page »